1/3 New #retirement research from @UCBerkeley calls out the fact that states with high levels of debt have cut benefits for public workers rather than raise revenue to fund pension promises. gspp.berkeley.edu/directories/fa…
2/3 But cutting benefits hasn't solved financial problems. Other experts, such as @RetirementRsrch Director Alicia Munnell, say legacy costs dating back decades are contributing to the financial stress of public plans. crr.bc.edu/special-projec…
3/3 As more research on the causes of pension debt comes out, it begs the question of how much today's workers should pay for costs they didn't incur. We think governments should be doing more to identify and ensure stable and sufficient funding for public pensions.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
44% of people sentenced to jail have a diagnosed mental illness
63% have a substance use disorder
45% suffer from chronic health problems
Jail often makes these conditions worse.
So how should cities respond to people in crisis? With data-driven justice. 1/
Today @Arnold_Ventures released the final reports from a multiyear pilot site test of using coordination and data to divert people in crisis away from jails and toward the services they need, such as healthcare or housing. 2/
These documents are three years in the making. Each site released its own final report that delves into how they used power of data to understand and better address the needs of frequent utilizers. 3/
As the nation grapples with unemployment & state budgets shrink amid #COVID-19, Nevada has a model that policy officials could implement and test to reemploy dislocated workers: It’s helping millions find jobs faster AND saving state money. arnoldventures.org/stories/nevada…#VPDebates
“I’m so grateful for #Gleevec. It keeps me alive. But the price tag ($10k/month) constantly hangs over my head.”
"When I'm on Enbrel, I don't have symptoms... But I also have to carry the fear knowing all this could be ripped away." Enbrel is priced at $6k per month.
First up: autoimmune drug Enbrel. Even though the primary patent on Enbrel expired in 2010, $AMGN has filed more than 50 additional patents on the drug to thwart cheaper competition, according to analysis by @IMAKglobal (1/) statnews.com/2020/09/29/dru…
Medicare spent hundreds of millions of $$$ more on Copaxone each year because of its inability to negotiate directly @46brooklyn@akesselheim
Even Teva’s own employees could not afford Copaxone at its price. One said she could no longer afford Copaxone because she would have to pay $1,673.33 out of pocket as compared to $12 for Mylan’s generic product.
After Mylan introduced a lower-priced generic version of Copaxone 40 mg/ml in October 2017, Teva implemented several new exclusionary tactics to limit generic competition and maintain profits.
First up: #Revlimid, a drug that costs $20k for a 28-day supply. The Committee reviewed more than 50k pages of internal communications & data from 2009 to now. Since Revlimid launched in '05, Celgene raised the price 22 times (1/) oversight.house.gov/sites/democrat…
After Bristol Myers Squibb obtained the rights to Revlimid last November, it raised the price again to $763/pill. The price has tripled in 15 years (2/)
Revlimid is a textbook case of profits over patients (3/)